Winner - Cases and Abstracts
Aki Otomo, St. George’s University
Cheddar is my 10 year-old Domestic Shorthair feline who I adopted in 2004 after he had sustained severe sacro-iliac trauma from being hit by a car at the age of 14 months. He initially presented with a necrotic tail pull injury, which required a short tail amputation with extensive urinary catheterization post-operatively.
By the age of 4 years, Cheddar exhibited numerous neurogenic issues including constipation, megacolon, urine retention from detrusor areflexia and fecal incontinence with pudendal nerve impingement. In 2011 his megacolon had progressed to a point where a subtotal colectomy was necessary. Subsequent sequelae included surgical dehiscience and septic peritonitis. In addition, his bladder atony became so severe he required a permanent low profile cystostomy tube for 14 months. Chiropractic adjustment, low level laser therapy and acupuncture allowed the removal of the cystostomy tube due to increased conscious voiding on Cheddar’s part, however he retains approximately 35mL of urine post-void. He currently suffers from chronic ascending multi-drug resistant urinary tract infections.
In December 2012, he was diagnosed with Inflammatory Bowel Disease (lymphactyic plasmacytic) with minimal villous lymphangiectasia and chronic mild gastritis. Initial therapy with diet change and Budesonide proved unsuccessful as his cachexia, weight loss and vomiting continued. Further Prednisone therapy resulted in a bladder wall fistula at his previous bladder pexy surgical site. Therefore, systemic immuno-supressants and steroids were ruled out as an ongoing treatment option for his IBD. After consulting with both his Internist Dr. Katie Baxter (BVSc, ACVIM) and Surgeon Dr. Alan Kuzma (DVM, ACVS), in July 2013, we enrolled Cheddar in Vet Stem’s IBD Developmental Program to use adipose derived adult mesenchymal stem cell therapy to potentially treat his IBD.
Background
Stem cell therapy is a fairly new form of treatment for a variety of diseases. Current clinical data has proven stem cell therapy to be effective for treatment of certain cases of equine osteoarthiritis, degenerative joint disease, osteochondrosis dissecans, ligament and tendon injuries, sub-chondral bone cysts, meniscal injuries and fractures (Nixon et al., 2008). In feline and canine patients, it is used most often for osteoarthirits (Black et al., 2007 and Black et al., 2008), orthopedic soft tissue injury, polyarthiritis and fractures. Although the complete understanding of the physiological mechanisms of stem cells have yet to be completely elucidated, stem cells are thought to promote healing and decrease inflammation and modulate inflammatory immune responses (De La Garza Rodea, 2011). They have the ability to modulate and control inflammatory cytokines and target areas of chronic inflammation (Fiorina et al., 2009) where they can potentially ‘re-set’ the inflammatory response through regeneration of normal cells and cell function (Zuk et al., 2002). Therefore, there is wide spread interest in researching stem cells to cure autoimmune diseases and disorders (Zuk et al., 2001).
Currently, there are various clinical trials being conducted on the use of stem cell therapy in felines with chronic renal disease with one such high profile trial being conducted at the Animal Medical Center in New York.
Click to read more ...